

DAFTAR PUSTAKA

1. Global diabetes cases to soar from 529 million to 1.3 billion by 2050 | The Institute for Health Metrics and Evaluation. <https://www.healthdata.org/news-events/newsroom/news-releases/global-diabetes-cases-soar-529-million-13-billion-2050>.
2. The Lancet. Diabetes: a defining disease of the 21st century. *The Lancet* **401**, 2087 (2023).
3. Diabetes Facets and Figures | International Diabetes Federation. <https://idf.org/about-diabetes/diabetes-facts-figures/>.
4. Indonesia diabetes report 2000 — 2045. <https://www.diabetesatlas.org/data/en/country/94/id.html>.
5. Davies, M. J. *et al.* Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* **45**, 2753–2786 (2022).
6. Diabetes and Mental Health | CDC. <https://www.cdc.gov/diabetes/managing/mental-health.html>.
7. Bystritsky, A., Khalsa, S. S., Cameron, M. E. & Schiffman, J. Current Diagnosis and Treatment of Anxiety Disorders. *Pharmacy and Therapeutics* **38**, 30 (2013).
8. DIAGNOSTIC AND STATISTICAL MANUAL OF DSM-5™.
9. Allen, M. J., Sabir, S. & Sharma, S. GABA Receptor. *Trends Pharmacol Sci* **2**, 62–64 (2023).
10. Wang, F., Yang, J., Pan, F., Ho, R. C. & Huang, J. H. Editorial: Neurotransmitters and Emotions. *Front Psychol* **11**, (2020).
11. Olivier, J. D. A. & Olivier, B. Translational studies in the complex role of neurotransmitter systems in anxiety and anxiety disorders. *Adv Exp Med Biol* **1191**, 121–140 (2020).
12. khalifeh, S. *et al.* Introduction to Neurocircuitry and Neurobiology of Anxiety. *Archives of Advances in Biosciences* **12**, 45–51 (2021).

13. Gkintoni, E. & Ortiz, P. S. Neuropsychology of Generalized Anxiety Disorder in Clinical Setting: A Systematic Evaluation. *Healthcare* 2023, Vol. 11, Page 2446 **11**, 2446 (2023).
14. Kenwood, M. M., Kalin, N. H. & Barbas, H. The prefrontal cortex, pathological anxiety, and anxiety disorders. *Neuropsychopharmacology* 2021 47:1 **47**, 260–275 (2021).
15. Molavi, P. *et al.* Repeated transcranial direct current stimulation of dorsolateral-prefrontal cortex improves executive functions, cognitive reappraisal emotion regulation, and control over emotional processing in borderline personality disorder: A randomized, sham-controlled, parallel-group study. *J Affect Disord* **274**, 93–102 (2020).
16. Eleonora, M. *et al.* Common and different neural markers in major depression and anxiety disorders: A pilot structural magnetic resonance imaging study. *Psychiatry Res Neuroimaging* **290**, 42–50 (2019).
17. Meier, S. M. & Deckert, J. Genetics of Anxiety Disorders. *Curr Psychiatry Rep* **21**, 1–8 (2019).
18. DIAGNOSTIC AND STATISTICAL MANUAL OF DSM-5 TM.
19. Feriante, J., Torrico, T. J. & Bernstein, B. Separation Anxiety Disorder. *Separation Anxiety* 1–73 (2023) doi:10.1542/pir.16.2.57.
20. Priscilla Wong, by, is, W. & Wong, P. Selective Mutism: A Review of Etiology, Comorbidities, and Treatment. *Psychiatry (Edgmont)* **7**, 23 (2010).
21. Oar, E. L., Lavell, C. & Ollendick, T. H. Specific Phobia. *Encyclopedia of Mental Health, Third Edition: Volume 1-3* **3**, V3-343-V3-352 (2023).
22. Kessler, R. C., Wai, T. C., Demler, O. & Walters, E. E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* **62**, 617–627 (2005).
23. Shin, J., Grossman, J. T., Rodriguez, C. R. & Rodebaugh, T. L. Social Anxiety Disorder. *Comprehensive Clinical Psychology, Second Edition* **6**, 373–383 (2022).
24. Cackovic, C., Nazir, S. & Marwaha, R. Panic Disorder. *StatPearls* (2023).

25. Bourenane, S. & Ghomres, A. The Psychological Diagnosis of a Panic Disorder. *Technium Social Sciences Journal* **37**, (2022).
26. Munir, S. & Takov, V. Generalized Anxiety Disorder. *StatPearls* (2022).
27. Substance/Medication-Induced Anxiety Disorder > Clinical Keywords > Yale Medicine. <https://www.yalemedicine.org/clinical-keywords/substancemedication-induced-anxiety-disorder>.
28. Tafet, G. E. & Nemeroff, C. B. Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis. *Front Psychiatry* **11**, 529446 (2020).
29. Laux, G. Serotonin Reuptake Inhibitors: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline. *NeuroPsychopharmacotherapy* 1–13 (2021) doi:10.1007/978-3-319-56015-1_413-1.
30. Gosmann, N. P. *et al.* Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. *PLoS Med* **18**, e1003664 (2021).
31. Balon, R. & Starcevic, V. Role of benzodiazepines in anxiety disorders. *Adv Exp Med Biol* **1191**, 367–388 (2020).
32. Luong, H. K., Drummond, S. P. A. & Norton, P. J. Elements of the therapeutic relationship in CBT for anxiety disorders: A systematic review. *J Anxiety Disord* **76**, 102322 (2020).
33. Horigome, T. *et al.* Virtual reality exposure therapy for social anxiety disorder: a systematic review and meta-analysis. *Psychol Med* **50**, 2487–2497 (2020).
34. Hofmann, S. G., Andreoli, G., Carpenter, J. K. & Curtiss, J. Depression and Anxiety Disorders: Benefits of Exercise, Yoga, and Meditation. *Am Fam Physician* **99**, 620–627 (2019).
35. Mersha, A. G., Tollosa, D. N., Bagade, T. & Eftekhari, P. A bidirectional relationship between diabetes mellitus and anxiety: A systematic review and meta-analysis. *J Psychosom Res* **162**, 110991 (2022).

36. Chaturvedi, S. K. *et al.* More anxious than depressed: prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus. *Gen Psychiatr* **32**, 15 (2019).
37. González, P., Lozano, P., Ros, G. & Solano, F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. *Int J Mol Sci* **24**, (2023).
38. Mouri, Mi. & Badireddy, M. Hyperglycemia. *Essence of Anesthesia Practice E-Book* 189 (2023) doi:10.1016/B978-1-4377-1720-4.00168-0.
39. Dilworth, L., Facey, A. & Omoruyi, F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. *International Journal of Molecular Sciences* 2021, Vol. 22, Page 7644 **22**, 7644 (2021).
40. Liman, M. N. P. & Jialal, I. Physiology, Glycosuria. *StatPearls* (2023).
41. Polydipsia - Excessive Thirst Causes and Symptoms. <https://www.diabetes.co.uk/symptoms/polydipsia.html>.
42. Smith, R. L., Soeters, M. R., Wüst, R. C. I. & Houtkooper, R. H. Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease. *Endocr Rev* **39**, 489 (2018).
43. Maisel, P., Baum, E. & Donner-Banzhoff, N. Fatigue as the Chief Complaint: Epidemiology, Causes, Diagnosis, and Treatment. *Dtsch Arztebl Int* **118**, 566 (2021).
44. Anandhanarayanan, A., Teh, K., Goonoo, M., Tesfaye, S. & Selvarajah, D. Diabetic Neuropathies. *Endotext* (2022).
45. Dilworth, L., Facey, A. & Omoruyi, F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. *International Journal of Molecular Sciences* 2021, Vol. 22, Page 7644 **22**, 7644 (2021).
46. McCorry, L. K. Physiology of the Autonomic Nervous System. *Am J Pharm Educ* **71**, (2007).
47. Daviu, N., Bruchas, M. R., Moghaddam, B., Sandi, C. & Beyeler, A. Neurobiological links between stress and anxiety. *Neurobiol Stress* **11**, 100191 (2019).

48. Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T. & Sahebkar, A. Molecular mechanisms linking stress and insulin resistance. *EXCLI J* **21**, 317 (2022).
49. Favero, V. *et al.* Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside. *International Journal of Molecular Sciences* 2022, Vol. 23, Page 673 **23**, 673 (2022).
50. Morais, J. B. S. *et al.* Association Between Cortisol, Insulin Resistance and Zinc in Obesity: a Mini-Review. *Biol Trace Elem Res* **191**, 323–330 (2019).
51. Mouri, Mi. & Badireddy, M. Hyperglycemia. *Essence of Anesthesia Practice E-Book* 189 (2023) doi:10.1016/B978-1-4377-1720-4.00168-0.
52. Siddiqui, A. *et al.* Association of oxidative stress and inflammatory markers with chronic stress in patients with newly diagnosed type 2 diabetes. *Diabetes Metab Res Rev* **35**, e3147 (2019).
53. James, K. A., Stromin, J. I., Steenkamp, N. & Combrinck, M. I. Understanding the relationships between physiological and psychosocial stress, cortisol and cognition. *Front Endocrinol (Lausanne)* **14**, (2023).
54. Nandam, L. S., Brazel, M., Zhou, M. & Jhaveri, D. J. Cortisol and Major Depressive Disorder—Translating Findings From Humans to Animal Models and Back. *Front Psychiatry* **10**, 476719 (2020).
55. La Rosa, C., Parolisi, R. & Bonfanti, L. Brain Structural Plasticity: From Adult Neurogenesis to Immature Neurons. *Front Neurosci* **14**, 512123 (2020).
56. Leschik, J., Lutz, B. & Gentile, A. Stress-Related Dysfunction of Adult Hippocampal Neurogenesis—An Attempt for Understanding Resilience? *International Journal of Molecular Sciences* 2021, Vol. 22, Page 7339 **22**, 7339 (2021).
57. Biondi, B., Kahaly, G. J. & Robertson, R. P. Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders. *Endocr Rev* **40**, 789 (2019).
58. Shahid, M. A., Ashraf, M. A. & Sharma, S. Physiology, Thyroid Hormone. *StatPearls* (2023).

59. Al-Suhaimi, E. A. & Khan, F. A. Thyroid Glands: Physiology and Structure. *Emerging Concepts in Endocrine Structure and Functions* 133–160 (2022) doi:10.1007/978-981-16-9016-7_5/COVER.
60. Iwamoto, Y. *et al.* Effect of Hyperglycemia-Related Acute Metabolic Disturbance on Thyroid Function Parameters in Adults. *Front Endocrinol (Lausanne)* **13**, 869869 (2022).
61. Khaleghzadeh-Ahangar, H., Talebi, A. & Mohseni-Moghaddam, P. Thyroid Disorders and Development of Cognitive Impairment: A Review Study. *Neuroendocrinology* **112**, 835–844 (2022).
62. Nicola, O.-M. *et al.* Oana-Maria Nicola (Marioara) *et al.*-Study of Cognitive Disfunctions in Thyroid Pathology Original Paper Study of Cognitive Disfunctions in Thyroid Pathology. doi:10.12865/CHSJ.47.02.16.
63. Martin, J. V. & Sarkar, P. K. Nongenomic roles of thyroid hormones and their derivatives in adult brain: are these compounds putative neurotransmitters? *Front Endocrinol (Lausanne)* **14**, (2023).
64. Hage, M., Kamenický, P. & Chanson, P. Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions. *Neuroendocrinology* **108**, 244–255 (2019).
65. Dao, L. N., Lippe, B., Laird, M. & Beierle, I. Human growth hormone. *Pharmaceutical Biotechnology: Fundamentals and Applications* 437–449 (2019) doi:10.1007/978-3-030-00710-2_20/COVER.
66. Hage, M., Kamenický, P. & Chanson, P. Growth Hormone Response to Oral Glucose Load: From Normal to Pathological Conditions. *Neuroendocrinology* **108**, 244–255 (2019).
67. Giacco, F. & Brownlee, M. Oxidative stress and diabetic complications. *Circ Res* **107**, 1058 (2010).
68. González, P., Lozano, P., Ros, G. & Solano, F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. *International Journal of Molecular Sciences* 2023, Vol. 24, Page 9352 **24**, 9352 (2023).

69. Priya Balaji, M., Rajeswari, D. & Rajeswari, D. V. Endothelial Dysfunction associated with Diabetes Mellitus linked to extracellular signal-regulated kinase and inflammatory pathways. *Article in Research Journal of Biotechnology* **18**, (2022).
70. Giacco, F. & Brownlee, M. Oxidative stress and diabetic complications. *Circ Res* **107**, 1058 (2010).
71. Pezhman, L., Tahrani, A. & Chimen, M. Dysregulation of Leukocyte Trafficking in Type 2 Diabetes: Mechanisms and Potential Therapeutic Avenues. *Front Cell Dev Biol* **9**, 624184 (2021).
72. Ghasemi-Dehnoo, M., Amini-Khoei, H., Lorigooini, Z. & Rafieian-Kopaei, M. Oxidative stress and antioxidants in diabetes mellitus. *Asian Pac J Trop Med* **13**, 431–438 (2020).
73. Shohag, S. *et al.* Perspectives on the Molecular Mediators of Oxidative Stress and Antioxidant Strategies in the Context of Neuroprotection and Neurolongevity: An Extensive Review. *Oxid Med Cell Longev* **2022**, (2022).
74. Singh, A., Kukreti, R., Saso, L. & Kukreti, S. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. *Molecules* 2019, Vol. 24, Page 1583 **24**, 1583 (2019).
75. Puzio, M., Moreton, N. & O'Connor, J. J. Neuroprotective strategies for acute ischemic stroke: Targeting oxidative stress and prolyl hydroxylase domain inhibition in synaptic signalling. *Brain Disord* **5**, 100030 (2022).
76. Fekri, K., Nayebi, A. M., Sadigh-Eteghad, S., Farajdokht, F. & Mahmoudi, J. The Neurochemical Changes Involved in Immobilization Stress-Induced Anxiety and Depression: Roles for Oxidative Stress and Neuroinflammation. *Neurochemical Journal* 2020 14:2 **14**, 133–149 (2020).
77. Naranjo, C., Ortega-Jiménez, P., del Reguero, L., Moratalla, G. & Failde, I. Relationship between diabetic neuropathic pain and comorbidity. Their impact on pain intensity, diabetes complications and quality of life in patients with type-2 diabetes mellitus. *Diabetes Res Clin Pract* **165**, 108236 (2020).

78. Martino, G. *et al.* As time goes by: Anxiety negatively affects the perceived quality of life in patients with type 2 diabetes of long duration. *Front Psychol* **10**, 469903 (2019).
79. Hill-Briggs, F. *et al.* Social Determinants of Health and Diabetes: A Scientific Review. *Diabetes Care* **44**, 258–279 (2021).
80. Powers, M. A. *et al.* Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. *Diabetes Care* **43**, 1636–1649 (2020).
81. Ryu, S. & Fan, L. The Relationship Between Financial Worries and Psychological Distress Among U.S. Adults. *J Fam Econ Issues* **44**, 16 (2023).
82. Nexø, M. A., Pedersen, J., Cleal, B. & Bjorner, J. B. Increased risk of long-term sickness absence, lower rate of return to work and higher risk of disability pension among people with type 1 and type 2 diabetes mellitus: a Danish retrospective cohort study with up to 17 years' follow-up. *Diabetic Medicine* **37**, 1861–1865 (2020).
83. Patel, M. R. Social Determinants of Poor Management of Type 2 Diabetes Among the Insured. *Curr Diab Rep* **20**, 1–6 (2020).
84. Balkhi, B. *et al.* Oral antidiabetic medication adherence and glycaemic control among patients with type 2 diabetes mellitus: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. *BMJ Open* **9**, e029280 (2019).
85. Mendes, R., Martins, S. & Fernandes, L. Adherence to Medication, Physical Activity and Diet in Older Adults With Diabetes: Its Association With Cognition, Anxiety and Depression. *J Clin Med Res* **11**, 583 (2019).
86. Adu, M. D., Malabu, U. H., Malau-Aduli, A. E. O. & Malau-Aduli, B. S. Enablers and barriers to effective diabetes self-management: A multi-national investigation. *PLoS One* **14**, e0217771 (2019).

87. Martino, G. *et al.* Alexithymia and Psychological Distress Affect Perceived Quality of Life in Patients with Type 2 Diabetes Mellitus. *Mediterranean Journal of Clinical Psychology* **7**, 1–15 (2019).
88. Bener, A., Ozturk, M. & Yildirim, E. Association between Depression, Anxiety and Stress Symptoms and Glycemic Control in Diabetes Mellitus Patients. *Int J Clin Endocrinol* **1**, (2017).
89. Jarang, P., Atau Hampir, S., Pernah, T., Hampir, J. & Selalu, S. *Zung Anxiety Self-Assessment Scale Versi Bahasa Indonesia Untuk Pasien Tuberkulosis*.
90. View of Analisis Hubungan Lama Menderita Diabetes Mellitus Dengan Kualitas Hidup Penderita Diabetes Mellitus. <https://ejurnaladchkdr.com/index.php/jik/article/view/84/77>.
91. VALIDASI 8-ITEM MORISKY MEDICATION ADHERENCE SCALE VERSI INDONESIA PADA PASIEN HIPERTENSI DEWASA DI PUSKESMAS KABUPATEN SLEMAN DAN KOTA YOGYAKARTA. <https://etd.repository.ugm.ac.id/penelitian/detail/109818>.